Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Market Cap	$16.18M	P/E Ratio	N/A
52W High	$1.55	52W Low	$0.23
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-43.9%	52W Position	9.3%
Overall Score	42	Value Score	60
Quality Score	--	Technical Score	25

EPS Current Est	$-0.79	EPS Next Est	$-0.39
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CODX	$0.35	+8.66%	959.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CODX	$0.35	+8.7%	959.86K
3
4
5
6

CODX

CODX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Co-Diagnostics Inc. Data in Excel

Get Co-Diagnostics Inc. Data in Excel